- Home
- PINC vs VRDN Comparison
PINC vs VRDN Comparison
Compare PINC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINC
- VRDN
- Stock Information
- Founded
- PINC 2013
- VRDN 2006
- Country
- PINC United States
- VRDN United States
- Employees
- PINC N/A
- VRDN N/A
- Industry
- PINC Other Consumer Services
- VRDN Medical Specialities
- Sector
- PINC Consumer Discretionary
- VRDN Health Care
- Exchange
- PINC Nasdaq
- VRDN Nasdaq
- Market Cap
- PINC 1.8B
- VRDN 1.5B
- IPO Year
- PINC 2013
- VRDN N/A
- Fundamental
- Price
- PINC $26.03
- VRDN $18.56
- Analyst Decision
- PINC Hold
- VRDN Strong Buy
- Analyst Count
- PINC 7
- VRDN 11
- Target Price
- PINC $24.29
- VRDN $38.80
- AVG Volume (30 Days)
- PINC 1.9M
- VRDN 877.4K
- Earning Date
- PINC 11-04-2025
- VRDN 08-06-2025
- Dividend Yield
- PINC 3.21%
- VRDN N/A
- EPS Growth
- PINC N/A
- VRDN N/A
- EPS
- PINC 0.22
- VRDN N/A
- Revenue
- PINC $1,012,647,000.00
- VRDN $305,000.00
- Revenue This Year
- PINC N/A
- VRDN N/A
- Revenue Next Year
- PINC $1.86
- VRDN $35,092.81
- P/E Ratio
- PINC $116.58
- VRDN N/A
- Revenue Growth
- PINC N/A
- VRDN 5.90
- 52 Week Low
- PINC $17.23
- VRDN $9.90
- 52 Week High
- PINC $27.26
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PINC 65.02
- VRDN 54.39
- Support Level
- PINC $25.44
- VRDN $18.12
- Resistance Level
- PINC $26.32
- VRDN $20.05
- Average True Range (ATR)
- PINC 0.89
- VRDN 1.02
- MACD
- PINC -0.05
- VRDN -0.03
- Stochastic Oscillator
- PINC 70.92
- VRDN 50.50
About PINC Premier Inc.
Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).